German Hodgkin Study Group Since 1978 and with more than 15,000 randomised patients the German Hodgkin Study Group aims to further optimize and standardize Hodgkin lymphoma diagnostics, treatment and follow-up care. On this side we would like to give you further information about Hodgkin lymphoma, current treatment strategies and the activities of the GHSG. The side aims to reach physicians as well as patients and interested laities. Get in touch If you should miss any required information don’t hesitated to contact us. You will find an overview of responsible persons and our review institutes here. Latest news of the German Hodgkin Study Group (GHSG): new standard in the therapy of early stage Hodgkin lymphoma
Patients with early stage Hodgkin lymphoma who are treated with a combination of chemotherapy followed by radiotherapy have very good chances of recovery today. The aim of the GHSG’s recent trials was therefore to reduce the side effects of treatment while maintaining healing rates. The results of the GHSG’s HD10 trial for early stage Hodgkin patients have now been published in the worldwide leading medical journal, the New England Journal of Medicine. The international multicenter HD10 trial included 1370 patients from 329 centers in Germany, Switzerland, Austria, Czech Republic and the Netherlands. The trial demonstrated that a short chemotherapy consisting of 2 cycles of ABVD followed by radiation of the involved lymph node regions is the ideal therapeutic combination. With this combination the intensity of radiotherapy can even be reduced by 30% without causing an impairment of healing results. The side effects of this short-time treatment are considerably lower. It can also be expected that this will lead to a clear reduction of treatment-induced late toxicities.
[download paper]
|
